1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Puerto Rico Pharmaceuticals and Healthcare Report Q4 2016

Puerto Rico Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 91 pages

Includes 3 FREE quarterly updates

BMI View:

An expected increase in US government funding to strengthen Puerto Rico's healthcare systemwill support pharmaceutical and healthcare sector growth in the commonwealth over the next few years.While the US administration will continue to seek legislative removal of Puerto Rico's Medicaid fundinglimitations over the coming months, the increasing risk posed by the Zika virus outbreak in the territory willpush for a rise in healthcare funding to become a priority. That said, market growth rates in severalsegments, including pharmaceuticals, are set to face headwinds due to Puerto Rico's economic recession.

Headline Expenditure Projections

- Pharmaceuticals: USD3.81bn in 2015 to USD3.82bn in 2016; +0.2%. Forecast in line with last quarter.

- Healthcare: USD8.06bn in 2015 to USD8.37bn in 2016; +3.8%. Forecast broadly in line with lastquarter.Risk/Reward IndexIn Q416, we have revised upwards Puerto Rico's Risk/Reward Index score to 65.7 from 64.5 in the lastquarter (out of 100). The score revision was driven by an improvement in the Industry Rewards index.Puerto Rico continues to stand as the third most attractive market to pharmaceutical investors in theAmericas region, behind the US and Canada. Puerto Rico's score is driven by high spending per capita onmedicine and high patent respect and business environment scores, but dragged down by a small marketsize and low sector value growth.Latest Updates

- In August 2016, Inovio Pharmaceuticals initiated a trial of its preventative Zika vaccine, GLS-5700, inPuerto Rico. Inovio, which is developing GLS-5700 in collaboration with GeneOne Life Science andacademic collaborators from the US and Canada, commenced the first FDA-approved human trial of aZika vaccine in June 2016.

Table Of Contents

Puerto Rico Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Puerto Rico 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Puerto Rico 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Puerto Rico 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Puerto Rico 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Puerto Rico 2012-2020) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Puerto Rico 2012-2020) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Puerto Rico 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Puerto Rico 2014-2020) 29
Pharmaceuticals and Healthcare Risk/Reward Index 30
Americas Risk/Reward Index 30
Puerto Rico Risk/Reward Index 37
Rewards 37
Risks 38
Regulatory Review 39
Table: Incentives, Benefits And Discounts For Pharmaceutical Manufacturers 41
Pricing Regime 42
Reimbursement Regime 43
Market Overview 44
Healthcare Sector 45
Research and Development 49
Clinical Trials 51
Epidemiology 52
Competitive Landscape 55
Research-Based Industry 56
Table: Major International Drugmakers In Puerto Rico 56
Table: Puerto Rico - Multinationals' Operations 59
Table: Multinational Company Activity, 2015 60
Generic Drugmakers 61
Pharmaceutical Distribution 62
Pharmaceutical Retail Sector 62
Company Profile 64
Abbott Laboratories 64
Eli Lilly 67
GlaxoSmithKline 70
Merck 73
Novartis 76
Sanofi 78
Demographic Forecast 80
Table: Population Headline Indicators (Puerto Rico 1990-2025) 81
Table: Key Population Ratios (Puerto Rico 1990-2025) 81
Table: Urban/Rural Population and Life Expectancy (Puerto Rico 1990-2025) 82
Table: Population By Age Group (Puerto Rico 1990-2025) 82
Table: Population By Age Group % (Puerto Rico 1990-2025) 83
Glossary 85
Methodology 87
Pharmaceutical Expenditure Forecast Model 87
Healthcare Expenditure Forecast Model 87
Notes On Methodology 88
Risk/Reward Index Methodology 89
Index Overview 90
Table: Pharmaceutical Risk/Reward Index Indicators 90
Indicator Weightings 91

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.